TY  - JOUR
AU  - Zhang, Xin-Wen
AU  - Huck, Katrin
AU  - Jähne, Kristine
AU  - Cichon, Frederik
AU  - Sonner, Jana
AU  - Ufer, Friederike
AU  - Bauer, Simone
AU  - Woo, Marcel Seungsu
AU  - Green, Ed
AU  - Lu, Kevin
AU  - Kilian, Michael
AU  - Friese, Manuel A
AU  - Platten, Michael
AU  - Sahm, Katharina
TI  - Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma.
JO  - OncoImmunology
VL  - 10
IS  - 1
SN  - 2162-402X
CY  - Abingdon
PB  - Taylor & Franics
M1  - DKFZ-2021-01153
SP  - 1920739
PY  - 2021
N1  - #EA:D170#LA:D170# / #DKFZ-MOST-Ca188#
AB  - Dendritic cell (DC) vaccination has proven to be an effective and safe adjuvant for cancer immunotherapies. As the presence of DCs within the tumor microenvironment promotes adaptive antitumor immunity, enhancement of DC migration toward the tumor microenvironment following DC vaccination might represent one possible approach to increase its therapeutic efficacy. While recent findings suggest the activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) as critical regulator of DC migration in the context of autoimmune diseases, we aimed to investigate the impact of Arc/Arg3.1 expression for DC-based cancer vaccines. To this end, DC migration capacity as well as the induction of T cell-mediated antitumor immunity was assessed in an experimental B16 melanoma model with Arc/Arg3.1-/- and Arc/Arg3.1-expressing BMDCs applied as a subcutaneous vaccine. While antigen presentation on DCs was critical for unleashing effective T cell mediated antitumor immune responses, Arc/Arg3.1 expression enhanced DC migration toward the tumor and secondary lymphoid organs. Moreover, Arc/Arg3.1-expressing BMDCs shape the tumor immune microenvironment by facilitating tumor recruitment of antigen-specific effector T cells. Thus, Arc/Arg3.1 may represent a novel therapeutic target in DCs in order to increase the therapeutic efficacy of DC vaccination.
KW  - Adoptive immunotherapy (Other)
KW  - CD8-positive T-lymphocytes (Other)
KW  - dendritic cells (Other)
KW  - melanoma (Other)
KW  - tumor microenvironment (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:34026332
C2  - pmc:PMC8128181
DO  - DOI:10.1080/2162402X.2021.1920739
UR  - https://inrepo02.dkfz.de/record/168951
ER  -